The therapeutic community is buzzing with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s exhibiting significant potential in clinical trials for managing obesity. Unlike some existing weight loss solutions, retatrutide appears to offer a significant substantial loss in body size and enhance metabolic function, parti